• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

AVAPROMISE:一项通过行为改变提高原发性高血压患者依从性的随机临床试验。

AVAPROMISE: A randomized clinical trial for increasing adherence through behavioural modification in essential hypertension.

作者信息

Hamet Pavel, Campbell Norman, Curnew Greg, Eastwood Clive, Pradhan Ashish

机构信息

Centre Hospitalier de l'Universite de Montreal, University of Montreal, Montreal, Quebec;

出版信息

Exp Clin Cardiol. 2002 Winter;7(4):165-72.

PMID:19644587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2716987/
Abstract

BACKGROUND

Patients with hypertension often do not adhere to their medications.

OBJECTIVE

To improve medication adherence in patients with essential hypertension by modifying their behaviours.

PATIENTS AND METHODS

From general practice settings, 4864 patients with essential hypertension were recruited and randomly assigned to receive the angiotensin receptor blocker irbesartan (Avapro) with (intervention group) or without (nonintervention group) a behavioural modification program (Avapromise) based on a model of change. Patients were followed up for 12 months. Patients were subgrouped based on their stage of change in the behavioural change continuum, and the intervention was tailored to address the needs of the particular subgroup. The primary efficacy measure was rate and time to discontinuation with irbesartan.

RESULTS

At the end of the study, there was no significant difference in the discontinuation rates between the intervention (25.4%, 95% CI 23.7 to 27.2) and nonintervention (25.5%, 95% CI 23.8 to 27.3) groups (P=0.94). The time to discontinuation (P=0.87) and the extrapolated rate of discontinuation estimated from the Kaplan-Meir curve (intervention 23.1%, 95% CI 21.3 to 24.8; nonintervention 23.5%, 95% CI 21.8 to 25.3) were not different between the groups.

CONCLUSIONS

This behavioural modification intervention based on a model of change was not efficacious at increasing rates of adherence in patients with essential hypertension in this setting. More individualized interventions may be required to increase adherence in this population.

摘要

背景

高血压患者常常不坚持服药。

目的

通过改变行为来提高原发性高血压患者的药物依从性。

患者与方法

从全科医疗环境中招募了4864例原发性高血压患者,并将其随机分为两组,一组接受基于改变模型的行为改变计划(阿伐普明思)并服用血管紧张素受体阻滞剂厄贝沙坦(安博维)(干预组),另一组只服用厄贝沙坦(非干预组)。对患者进行了12个月的随访。根据患者在行为改变连续体中的改变阶段进行亚组划分,并针对特定亚组的需求调整干预措施。主要疗效指标是厄贝沙坦停药率和停药时间。

结果

研究结束时,干预组(25.4%,95%可信区间23.7%至27.2%)和非干预组(25.5%,95%可信区间23.8%至27.3%)的停药率无显著差异(P=0.94)。两组之间的停药时间(P=0.87)以及根据Kaplan-Meir曲线估计的外推停药率(干预组23.1%,95%可信区间21.3%至24.8%;非干预组23.5%,95%可信区间21.8%至25.3%)也无差异。

结论

在这种情况下,这种基于改变模型的行为改变干预措施对于提高原发性高血压患者的依从率无效。可能需要更具个性化的干预措施来提高该人群的依从性。

相似文献

1
AVAPROMISE: A randomized clinical trial for increasing adherence through behavioural modification in essential hypertension.AVAPROMISE:一项通过行为改变提高原发性高血压患者依从性的随机临床试验。
Exp Clin Cardiol. 2002 Winter;7(4):165-72.
2
A Highly Tailored Text and Voice Messaging Intervention to Improve Medication Adherence in Patients With Either or Both Hypertension and Type 2 Diabetes in a UK Primary Care Setting: Feasibility Randomized Controlled Trial of Clinical Effectiveness.在英国初级医疗环境中,一项高度定制的文本和语音信息干预措施,用于改善患有高血压或2型糖尿病或两者兼有的患者的药物依从性:临床有效性的可行性随机对照试验
J Med Internet Res. 2020 May 19;22(5):e16629. doi: 10.2196/16629.
3
Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial.一种远程提供的量身定制的多组分方法对高脂血症、高血压和糖尿病患者加强服药依从性的影响:STIC2IT 整群随机临床试验
JAMA Intern Med. 2018 Sep 1;178(9):1182-1189. doi: 10.1001/jamainternmed.2018.3189.
4
5
Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.一项药学服务项目对药物依从性、持续性、血压及低密度脂蛋白胆固醇的影响:一项随机对照试验
JAMA. 2006 Dec 6;296(21):2563-71. doi: 10.1001/jama.296.21.joc60162. Epub 2006 Nov 13.
6
A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.一项关于厄贝沙坦对年龄≥65岁的轻度至中度高血压患者降压疗效及耐受性的多中心、随机、双盲研究。
Clin Ther. 2000 Oct;22(10):1213-24. doi: 10.1016/s0149-2918(00)83064-7.
7
Text Messaging to Improve Hypertension Medication Adherence in African Americans From Primary Care and Emergency Department Settings: Results From Two Randomized Feasibility Studies.通过短信提高非裔美国人在初级保健和急诊科环境中高血压药物治疗依从性:两项随机可行性研究的结果。
JMIR Mhealth Uhealth. 2017 Feb 1;5(2):e9. doi: 10.2196/mhealth.6630.
8
Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.血管紧张素阻断剂与血液透析患者肾功能进行性丧失:一项随机对照试验。
Am J Kidney Dis. 2014 Dec;64(6):892-901. doi: 10.1053/j.ajkd.2014.05.011. Epub 2014 Jul 8.
9
A Randomized Trial of a Multicomponent Intervention to Promote Medication Adherence: The Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial (TAKE-IT).一项多组分干预措施促进药物依从性的随机试验:青少年肾移植干预试验的依从性有效性(TAKE-IT)。
Am J Kidney Dis. 2018 Jul;72(1):30-41. doi: 10.1053/j.ajkd.2017.12.012. Epub 2018 Mar 27.
10
A Successful Multifaceted Trial to Improve Hypertension Control in Primary Care: Why Did it Work?一项成功的多方面改善基层医疗中高血压控制的试验:为何奏效?
J Gen Intern Med. 2015 Nov;30(11):1665-72. doi: 10.1007/s11606-015-3355-x.

引用本文的文献

1
Interventions for enhancing medication adherence.提高药物依从性的干预措施。
Cochrane Database Syst Rev. 2014 Nov 20;2014(11):CD000011. doi: 10.1002/14651858.CD000011.pub4.
2
Modes of delivery for interventions to improve cardiovascular medication adherence.改善心血管药物治疗依从性的干预措施的分娩方式。
Am J Manag Care. 2010;16(12):929-42.
3
Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review.改善心血管药物治疗依从性的干预措施中医生的效力:系统评价。
J Gen Intern Med. 2010 Oct;25(10):1090-6. doi: 10.1007/s11606-010-1387-9. Epub 2010 May 13.

本文引用的文献

1
How to improve adherence with prescribed treatment in hypertensive patients?如何提高高血压患者对规定治疗的依从性?
J Cardiovasc Pharmacol. 2000;35 Suppl 3:S23-6. doi: 10.1097/00005344-200035063-00006.
2
Interventions for helping patients to follow prescriptions for medications.帮助患者遵医嘱用药的干预措施。
Cochrane Database Syst Rev. 2000(2):CD000011. doi: 10.1002/14651858.CD000011.
3
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.厄贝沙坦与氢氯噻嗪联合治疗轻至中度高血压的疗效研究
Am J Hypertens. 1999 Aug;12(8 Pt 1):797-805. doi: 10.1016/s0895-7061(99)00053-9.
4
Adherence to pharmacologic management of hypertension.高血压药物治疗的依从性。
Can J Public Health. 1998 Sep-Oct;89(5):I16-8. doi: 10.1007/BF03404494.
5
Validity versus generalizability in clinical trial design and conduct.临床试验设计与实施中的效度与普遍性
J Card Fail. 1998 Sep;4(3):239-41. doi: 10.1016/s1071-9164(98)80014-6.
6
Continuation of initial antihypertensive medication after 1 year of therapy.治疗1年后继续使用初始抗高血压药物。
Clin Ther. 1998 Jul-Aug;20(4):671-81. doi: 10.1016/s0149-2918(98)80130-6.
7
Lessons from hypertension trials.高血压试验的经验教训。
Am J Med. 1998 Jun 22;104(6A):50S-53S. doi: 10.1016/s0002-9343(98)00188-0.
8
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.两种血管紧张素II受体拮抗剂(厄贝沙坦和氯沙坦)治疗轻至中度高血压的疗效比较。厄贝沙坦/氯沙坦研究组。
Am J Hypertens. 1998 Apr;11(4 Pt 1):445-53. doi: 10.1016/s0895-7061(97)00491-3.
9
A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.一项关于血管紧张素II受体拮抗剂厄贝沙坦与全剂量范围依那普利治疗轻至中度高血压的随机双盲比较研究。
J Hum Hypertens. 1998 Mar;12(3):203-8. doi: 10.1038/sj.jhh.1000591.
10
Awareness, treatment, and control of hypertension in Canada.加拿大高血压的知晓、治疗与控制情况
Am J Hypertens. 1997 Oct;10(10 Pt 1):1097-102. doi: 10.1016/s0895-7061(97)00224-0.